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Abstract
Various combinations of subunits assemble to form the NMDA-type glutamate receptor (NMDAR),
generating diversity in its functions. Here we review roles of the unique NMDAR subunit, NR3A,
which acts in a dominant-negative manner to suppress receptor activity. NR3A-containing NMDARs
display striking regional and temporal expression specificity, and, unlike most other NMDAR
subtypes, they have a low conductance, are only modestly permeable to Ca2+, and pass current at
hyperpolarized potentials in the presence of magnesium. While glutamate activates triheteromeric
NMDARs composed of NR1/NR2/NR3A subunits, glycine is sufficient to activate diheteromeric
NR1/NR3A-containing receptors. NR3A dysfunction may contribute to neurological disorders
involving NMDARs, and the subunit offers an attractive therapeutic target given its distinct
pharmacological and structural properties.
1. Introduction
N-methyl-D-aspartate receptors (NMDARs) are activated by glutamate, the most common
excitatory neurotransmitter in the central nervous system, and are essential for the proper
development of cortical circuitry and synaptic function (Cull-Candy et al., 2001; Lau and
Zukin, 2007; McBain and Mayer, 1994; Perez-Otano and Ehlers, 2004). Dysfunction of
NMDARs has been implicated in a variety of pathological conditions including schizophrenia
(Mueller and Meador-Woodruff, 2004), neurodegenerative disease (Bonuccelli and Del Dotto,
2006; Fan and Raymond, 2007; Wenk, 2006), stroke (Martin et al., 1998), white-matter injury
(Karadottir et al., 2005; Micu et al., 2006; Salter and Fern, 2005), and neuropathic pain (Dubner
and Ruda, 1992).
Great diversity exists in NMDAR subtypes. The NMDAR is thought to be a tetrameric
transmembrane channel (Laube et al., 1998; Rosenmund et al., 1998; Ulbrich and Isacoff,
2007) composed of combinations of the obligatory NR1 subunit with NR2 and/or NR3 subunits
(Furukawa et al., 2005; Schorge and Colquhoun, 2003). The NR1 subunit exists as eight
functional splice variants (Durand et al., 1993; Durand et al., 1992; Hollmann et al., 1993;
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Mori and Mishina, 1995; Sugihara et al., 1992), while separate genes produce four types of
NR2 (NR2A-D) and two types of NR3 (NR3A-B) subunits (Ciabarra et al., 1995; Meguro et
al., 1992; Mishina et al., 1993; Monyer et al., 1992; Moriyoshi et al., 1991; Nishi et al.,
2001; Sucher et al., 1995). Each receptor subtype exhibits temporal and regional specificity
(Monyer et al., 1994; Sheng et al., 1994) and unique functional properties (Monyer et al.,
1992; Paoletti and Neyton, 2007) which are determined by the specific combination of subunits
assembled to form the heteromer. For instance, subunit composition determines receptor
properties such as glutamate affinity, receptor desensitization, and pharmacological sensitivity
(Cull-Candy and Leszkiewicz, 2004; Paoletti and Neyton, 2007). A major goal in neuroscience
is to characterize the contributions of individual subunit types to NMDAR function. Such
knowledge will increase our understanding of how NMDARs contribute to normal brain
development, as well as guide therapeutic strategies for treating pathologies associated with
NMDAR dysfunction.
While attention has focused on the role of NR2 subunits in neural function, much less is known
about how the more recently identified NR3 subunits, NR3A and NR3B, modify NMDAR
functions. This is surprising, given that NR3 subunits act in a novel, dominant-negative manner
to suppress NMDAR activity (Ciabarra et al., 1995; Sucher et al., 1995) (Matsuda et al.,
2002; Nishi et al., 2001). Interest in NR3A has grown with the observations that the subunit
influences dendritic spine density (Das et al., 1998; Roberts et al., 2009), synapse maturation
(Roberts et al., 2009), memory consolidation (Roberts et al., 2009), cell survival (Nakanishi
et al., 2009), and may be involved in certain neuropathologies (Karadottir et al., 2005; Micu
et al., 2006; Mueller and Meador-Woodruff, 2004; Salter and Fern, 2005; Zhang et al.,
2002).
Although NR3A was identified over a decade ago, there have been few efforts to consolidate
knowledge of its functions and possible disease roles (although see (Cavara and Hollmann,
2008; Eriksson et al., 2007a). Here we provide a timely primer of NR3A, with a limited
discussion of NR3B, to summarize the major findings surrounding this receptor subunit and
its suggested roles in neuropathologies. Given the large number of disorders associated with
NMDAR dysfunction, and the paucity of studies that have examined the putative contribution
of NR3 subtypes, we anticipate that its unique structure, expression patterns, and function will
make it an important therapeutic target.
2. NR3A amino acid sequence and structure
NR3A was identified through sequence and structure homology to other GRIN (Glutamate
Receptor Ionotropic N-methyl-D-aspartate) genes, and originally termed ‘χ-1’ or ‘NMDAR-
like’ (NMDAR-L) (Ciabarra et al., 1995; Sucher et al., 1995). The GRIN3A gene localizes to
human chromosome 9q34.1, and consists of 9 exons spanning 1115 amino acids (Andersson
et al., 2001) (Figure 1). The high level of sequence homology between human and rodent NR3A
(93%) indicates that its function is likely similar between mammalian species (Andersson et
al., 2001; Eriksson et al., 2002). Most consensus sites are conserved between rodents and
humans, although the lack of gene equivalents in D. melanogaster and C. elegans suggests that
evolutionary changes may have necessitated the emergence of NR3 subtypes in vertebrates
(Matsuda et al., 2002). By sequence alignment, NR3A shares the greatest homology with
NR3B (GRIN3B; 57%), having low identity with NR1 (27%) and NR2 subunits (24–29%) as
well as non-NMDA glutamate receptors (23%) (Andersson et al., 2001).
NR3A shares structural features with other ionotropic glutamate receptor subunits (Figure 2),
including a 4-pass transmembrane topology which forms the channel pore, a large extracellular
N-terminal ligand-binding domain with a putative signal peptide and multiple glycosylation
consensus sites, and a cytoplasmic tail. Like other NMDAR subunits, the intracellular C-
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terminus of NR3A contains sites potentially phosphorylated by protein kinases A and C (PKA,
PKC), protein tyrosine kinase (PTK), and calcium/calmodulin-dependent kinase II (CaMKII)
(Andersson et al., 2001;Ciabarra et al., 1995;Eriksson et al., 2002;Nishi et al., 2001;Sucher
et al., 1995), suggesting that phosphorylation could play critical roles in regulating NR3A
trafficking, signaling, and channel properties (Chen and Roche, 2007). NR3A also contains a
motif with two vicinal cysteine residues, CC(Y/K)G(Y/F)CID(I/L)L, required for redox
modulation (Andersson et al., 2001;Sucher et al., 1995;Sullivan et al., 1994), as well as an
intracellular RXR motif which may serve as an endoplasmic reticulum (ER) retention signal
(Perez-Otano et al., 2001) .
Despite similarities to other NMDAR subunits, NR3A exhibits a number of distinctive features.
As with other NMDAR subunits, the NR3A amino acid sequence encodes an extracellular bi-
lobed domain (split into S1 and S2 segments by membrane domains TM1, TM2, and TM3)
that determines ligand binding specificity. But unlike NR2 subunits, which bind glutamate, the
S1 region of the extracellular N-terminus and the S2 region of the extracellular loop between
TM3 and TM4 form a glycine binding pocket, a clamshell-like structure (Paas, 1998; Yao et
al., 2008; Yao and Mayer, 2006). Additionally, the second membrane pore loop (TM2) and
the third membrane pore loop (TM3) in both NR3A and NR3B are substantially different from
other NMDAR subunits. In NR1/NR2 NMDARs, an ion selectivity filter at TM2 is formed by
an interaction between asparagine (N) residues of NR1 (N-site) and NR2 subunits (N+1 site)
(Kuner et al., 1996). In NR3A subunits, however, the N-site is replaced by a glycine (G)
(Matsuda et al., 2002; Nishi et al., 2001; Sucher et al., 1995), and this residue apparently has
little influence upon ion selectivity (Wada et al., 2006). While NR3A-containing NMDARs
apparently lack the N and N+1 site selectivity filter, they appear to have a novel construction
of the outer vestibule that can influence ionic currents. Unlike NR1/NR2 NMDARs, the TM3
domain between NR1 and NR3A subunits has a symmetrical configuration that forms a ring
of threonines. This ring constricts the external vestibule and may account for the observed
reductions in Ca2+ permeability, ionic currents, and magnesium (Mg2+) sensitivity of NR3A-
containing NMDARs (Wada et al., 2006). Another distinct characteristic is that the C-termini
of NR3A and NR3B lack consensus sequences for PDZ domain protein-binding (Eriksson et
al., 2007a; Matsuda et al., 2002), prominent features of other glutamate receptor subunits that
permit stable anchoring to the postsynaptic density. Finally, with a calculated molecular weight
of ~125kD, NR3A is the most heavily glycosylated glutamate receptor subunit (Ciabarra and
Sevarino, 1997). The functional significance of this robust glycosylation is unclear, but it may
alter channel gating kinetics (Chazot et al., 1995; Covarrubias et al., 1989).
Alternative mRNA splicing is another means to modify NR3A functions. A 60-base pair insert
encoding an additional 20 amino acid sequence at the intracellular C-terminus has been
described in rodents, resulting in short (NR3A-s or NR3A-1) and long (NR3A-l or NR3A-2)
forms of NR3A (Eriksson et al., 2002; Sasaki et al., 2002; Sun et al., 1998) (Figure 1 and
Figure 2). The long splice variant NR3A-l, which contains putative PKA, PKC, and CaMKII
phosphorylation sites, is apparently lacking in human NR3A (Andersson et al., 2001; Eriksson
et al., 2002).
3. Developmental and regional expression
NR3A levels change dramatically over development and exhibit a unique spatiotemporal
expression pattern when compared to other NMDAR subunits. While NR3A expression is
grossly similar across mammalian species, there are some notable differences. Understanding
these distribution patterns will help predict how prospective NR3A agonists and antagonists
are likely to affect neural function. Because the existing data on NR3A expression patterns are
sometimes contradictory, the information is summarized here in tabular format to present an
overview of the consensus findings from brain tissue (Table 1).
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Overall, NR3A expression is low embryonically, peaks during early postnatal life, and
diminishes to much lower levels in adulthood. This expression profile is observed in many
regions of the brain and in different species (Table 1), suggesting that it may play a specific
role during postnatal neural development amongst mammals (Al-Hallaq et al., 2002;Bendova
et al., 2009;Ciabarra et al., 1995;Das et al., 1998;Eriksson et al., 2002;Eriksson et al.,
2007b;Goebel and Poosch, 1999;Henson et al., 2008;Mueller and Meador-Woodruff, 2003,
2004,2005;Naassila and Daoust, 2002;Nilsson et al., 2007b;Perez-Otano et al., 2006;Roberts et
al., 2009;Sasaki et al., 2002;Sucher et al., 1995;Sun et al., 1998;Sun et al., 2000;Wong et
al., 2002). Despite having a roughly similar expression profile across species, future studies
with a finer level of analysis may reveal important differences. Further heterogeneity of NR3A
expression across species and brain regions could also arise from differential expression of its
two splice variants (discussed above).
In contrast to NR3A, NR3B levels are low around postnatal day (P) 10 and gradually increase
into adulthood within the neocortex, hippocampus, striatum, cerebellum, brainstem, and spinal
cord (Andersson et al., 2001; Bendel et al., 2005; Eriksson et al., 2002; Matsuda et al., 2002;
Nishi et al., 2001; Wee et al., 2008) (Figure 3A). Given the functional similarities and high
sequence homology between NR3A and NR3B (57%) (Andersson et al., 2001), it is surprising
that these dominant-negative subunits have distinct temporal expression patterns in many of
the same brain regions.
Each NMDAR subunit (NR1, NR2A-D, and NR3A-B) exhibits a unique ontogenetic profile
(Ciabarra et al., 1995; Dunah et al., 1996; Fukaya et al., 2005; Laurie et al., 1997; Matsuda et
al., 2002; Monyer et al., 1994; Sheng et al., 1994; Sun et al., 1998; Watanabe et al., 1992)
(Figure 3A), consistent with its functional “signature” (Al-Hallaq et al., 2002; Goebel and
Poosch, 1999). The NR1 subunit is obligatory for NMDAR function and is present throughout
life. NR3A is developmentally expressed following a time course most similar to NR2D; both
are prominent in the first two postnatal weeks in overlapping brain regions (Ciabarra et al.,
1995; Dunah et al., 1996; Laurie et al., 1997; Monyer et al., 1994; Sun et al., 1998; Watanabe
et al., 1992). The developmental decreases of NR3A and NR2D expression are in contrast to
that of NR3B, NR2A, and NR2C, whose expression levels increase developmentally and peak
during the third postnatal week (Fukaya et al., 2005; Matsuda et al., 2002; Monyer et al.,
1994; Sheng et al., 1994) (Figure 3A). While both NR3A and NR2B are strongly expressed
early in development, NR3A (but not NR2B) levels exhibit a pronounced reduction during
postnatal maturation.
3.2 Cellular, laminar, and subcellular localization
NR3A and NR3B are expressed by multiple neuronal cell types, including interneurons,
pyramidal cells, motor neurons, trigeminal neurons, retinal ganglion and amacrine cells
(Ishihama et al., 2005; Ishihama and Turman, 2006; Matsuda et al., 2002; Mueller and Meador-
Woodruff, 2005; Nishi et al., 2001; Paarmann et al., 2005; Sucher et al., 2003). Although
NR3A is present in oligodendrocytes, it does not seem to be expressed in astrocytes (Ishihama
et al., 2005; Karadottir et al., 2005; Matsuda et al., 2002; Paarmann et al., 2005; Perez-Otano
et al., 2006; Salter and Fern, 2005). NR3B localization has been observed in most of the cells
located in adult cerebral cortex, hippocampus, striatum, cerebellum, and lumbar spinal cord.
This ubiquitous expression of NR3B parallels that of NR1 and suggests a role for NR3B in
adult NMDAR function (Wee et al., 2008). Data from NR3B knockout mice will be required
to determine the extent to which NR3B influences NMDAR-mediated transmission in the adult
central nervous system.
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Because of the inside-out pattern in which cortical lamination occurs, the high levels of NR3A
observed in layer 5 have raised the possibility that NR3A may play a role in establishing early
cortical circuits, perhaps by modulating Ca2+ influx and cell vulnerability to excitotoxicity
(Mueller and Meador-Woodruff, 2005; Sucher et al., 1995). NR3B also shows predominant
expression in layer 5, but the implications of this laminar specificity in the adult have not yet
been investigated.
Ultrastructurally, NR3A colocalizes with NR1 and NR2 subunits at postsynaptic membranes
of asymmetric (excitatory) synapses (Perez-Otano et al., 2006; Wong et al., 2002), although
it appears to be more abundant at perisynaptic and extrasynaptic sites than at the postsynaptic
density (PSD) in both juvenile and adult animals (Perez-Otano et al., 2006). The localization
of NR3A contrasts sharply with the PSD-centric localization of NR2A, but is similar to the
more lateral and extrasynaptic positioning of NR2B-containing receptors (Groc et al., 2006;
Racca et al., 2000). Biochemical fractionation studies confirm the ultrastructural data, and
show that NR3A is associated with membranous fractions, such as ER, Golgi, endosomes, and
synaptic membranes, but is not as enriched in PSDs as NR1 or NR2 subunits (Perez-Otano et
al., 2006). Future experiments are needed to determine (1) whether NR3A-containing receptors
shift from synaptic to extrasynaptic sites during development, as has been suggested for other
NMDAR subtypes (Kohr, 2006), or (2) whether their peri/extrasynaptic localization indicates
a graded and reciprocal organization of different NMDAR subtypes within the PSD that could
be fitted for sensing the varied patterns of glutamate release.
4. NR3 subunits exert a dominant-negative effect upon NMDAR function
The properties of typical NMDARs containing NR2A or NR2B subunits include channel block
by Mg2+ at hyperpolarized potentials, high permeability to Ca2+, and a subunit-specific
complement of protein binding partners (Kennedy et al., 2005; Matute et al., 1997). These
properties are critical to many forms of plasticity (Gustafsson and Wigstrom, 1988; Madison
et al., 1991) and profoundly influence the wiring of the nervous system and memory processes
(Bliss and Collingridge, 1993; Constantine-Paton et al., 1990). Receptors containing NR3A
or NR3B subunits have unique properties that differ from conventional NR1/NR2 heteromers.
In heterologous expression systems, NR3 subunits assemble into two functional receptor
combinations: (1) a heterodimer of NR1 and NR3 subunits that unexpectedly forms an
excitatory glycine receptor, and (2) a heterotrimeric complex of NR1, NR2, and NR3 subunits
that forms an NMDAR with novel properties and attenuated currents compared to NR1/NR2
NMDARs (Chatterton et al., 2002; Ciabarra et al., 1995; Das et al., 1998; Sucher et al.,
1995).
4.1 Triheteromeric NR3A-containing glutamate receptors
NR3A-containing NMDARs only sense glutamate when glutamate-binding NR2 subunits are
included (Ciabarra et al., 1995; Perez-Otano et al., 2001; Sucher et al., 1995). When NR1,
NR2A, and NR3 subunits are co-expressed in heterologous expression systems, single-channel
recordings reveal two populations of NMDA-evoked currents: one characterized by a large
conductance resembling the prototypical channel response of NR1/NR2A heteromers, and a
second population of smaller conductance, presumably due to channels containing NR3 (Das
et al., 1998; Perez-Otano et al., 2001; Sasaki et al., 2002; Ulbrich and Isacoff, 2008) (Figure
4B, C). The putative NR3-containing receptors exhibit dramatically reduced single-channel
open probabilities and longer mean open times (Perez-Otano et al., 2001; Sasaki et al.,
2002), but see (Das et al., 1998).
Along with generally decreasing ionic conductance through NMDARs, inclusion of NR3
subunits alters two of the most prominent properties of traditional NMDARs (NR1/NR2
heteromers). First, it causes a five- to ten-fold decrease in Ca2+ permeability, with the variation
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of the estimates likely reflecting differences between the recombinant systems employed (Das
et al., 1998; Matsuda et al., 2002; Perez-Otano et al., 2001; Sasaki et al., 2002; Tong et al.,
2008) (Figure 4). Second, NR3A-containing NMDARs are also almost completely insensitive
to Mg2+ block at hyperpolarized potentials (Sasaki et al., 2002), but see (Nishi et al., 2001).
Both the reduced Mg2+ sensitivity and Ca2+ permeability of NR3A-NMDARs have recently
been confirmed in neuronal cultures or hippocampal slices from transgenic mice
overexpressing NR3A and knockout mice lacking NR3A (Roberts et al., 2009; Tong et al.,
2008) (Table 2). As previously discussed in Section 2, the observed physiological
characteristics of NR3A-containing NMDARs most likely result from the formation of a
narrow constriction of the outer vestibule along the TM3 pore-forming region of the NR3
subunits.
4.2 Diheteromeric NR3A-containing excitatory glycine receptors
The physiological significance of NR1/NR3 excitatory glycine receptors remains an open
question because of conflicting reports in vitro, and this subunit combination has yet to be
documented in vivo. Despite evidence that NR1/NR3 complexes are targeted to the plasma
membrane in heterologous systems (Madry et al., 2007; Perez-Otano et al., 2001), early reports
failed to record NMDAR-mediated responses to glutamate or NMDA application in the
absence of NR2 subunits (Ciabarra et al., 1995; Das et al., 1998; Perez-Otano et al., 2001;
Sucher et al., 1995). Instead of exhibiting a responsiveness to glutamate, NR1/NR3 complexes
were found to be sensitive to glycine application (Chatterton et al., 2002). This finding is
consistent with the observation that the NR3A ligand binding domain has very high affinity
for glycine, but is relatively insensitive to glutamate (Nilsson et al., 2007a; Yao and Mayer,
2006). Glycine application to NR1/NR3 diheteromers evokes a large inward current, indicating
that these receptors form an excitatory glycine receptor. The ion permeability of NR1/NR3
diheteromers was similar to that of NR3-containing triheteromers, in that the currents were
relatively impermeable to Ca2+ and insensitive to Mg2+ block (Chatterton et al., 2002; Das et
al., 1998; Nishi et al., 2001; Perez-Otano et al., 2001; Sasaki et al., 2002). Additionally, while
both NR1/NR3A and NR1/NR3B receptors form in Xenopus oocytes (Chatterton et al.,
2002), NR3 subunits fail to assemble with NR1 subunits in HEK cells unless both NR3A and
NR3B are present (Smothers and Woodward, 2007).
Chatterton and colleagues (2002) reported that bath application of glycine to cerebrocortical
cultures elicited a bursting response, which they interpreted as evidence that excitatory glycine
receptors exist in the brain. Furthermore, single-channel recordings from outside-out patches
from these cultured neurons exhibited channel properties similar to NR1/NR3 receptors in
heterologous systems. However, this bursting response to glycine can be found in cultures in
which NR1 subunits, and hence all NMDARs, are lacking (Matsuda et al., 2003). Given that
the presence of NR1 is required for NR3 subunits to exit the ER and form stable complexes in
the plasma membrane (Perez-Otano et al., 2001), these data indicate that the glycine-induced
bursting may be independent of NR3 subunits. The existence of glycinergic NR1/NR3
receptors was also questioned by studies finding no evidence for excitatory glycine currents
in cultured neurons from mice genetically engineered to overexpress NR3A (Tong et al.,
2008) (Table 2).
The high affinity of NR1/NR3 receptors for glycine suggests that, if found in vivo, this receptor
combination might be saturated by physiological concentrations of glycine (Yao and Mayer,
2006). Thus, these receptors would serve to keep neurons in a more depolarized state and,
depending upon their subcellular localization, could have a profound influence upon synaptic
transmission and action potential firing.
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The study of NR3A pharmacology is still in its infancy. However, it is clear that NR3A shares
more commonalities with NR1 than it does with NR2 subunits. For instance, NR1 binds glycine
(Hirai et al., 1996; Yao and Mayer, 2006) whereas NR2 subunits bind glutamate (Laurie et
al., 1997), and receptors formed by NR1 and NR3A bind glycine with much higher affinity
than do NR1/NR2 receptors (Chatterton et al., 2002). Studies of the rodent ligand binding
domain and human full-length protein confirm that glycine binds NR3A with much higher
affinity than it binds NR1 [rodent NR3A, Kd = 40 nM, 650 times less than that for NR1 (Yao
and Mayer, 2006), and human NR3A, Kd = 535 nM (Nilsson et al., 2007a)]. The lower affinity
for glycine of human NR3A compared to rodent NR3A could be due to species differences or
differences between the full-length protein and the truncated soluble ligand binding domain.
In both human and rodent, NR3A is likely saturated by its preferred endogenous ligand, glycine,
at physiological concentrations (Yao and Mayer, 2006). The NR3A ligand binding domain has
a low affinity for glutamate (Kd = 9.6 mM) (Yao and Mayer, 2006), and the presumptive
activation of NR1/NR2/NR3A triheteromeric receptors by glutamate or NMDA is almost
certainly due to the binding of these agonists to NR2 subunits.
D-serine is a potent glycine site agonist of NMDARs (Kleckner and Dingledine, 1988), and
accordingly, binding assays demonstrate that D-serine also binds human and rat NR3A with
high affinity (Nilsson et al., 2007a; Yao and Mayer, 2006). One electrophysiological study
indicated that D-serine behaves as a functional antagonist of NR1/NR3A receptors (Chatterton
et al., 2002). This differs from other reports, and may be due to the fact that D-serine produces
a rapid desensitization resembling an antagonist block (Yao and Mayer, 2006). Another
possibility is that assembly of NR3A with other subunits (e.g. NR1) produces allosteric
interactions that alter ligand binding properties (Laurie and Seeburg, 1994). The ligand binding
properties of NR3A, and if/how they differ when NR3A co-assembles with other NMDAR
subunits have yet to be determined. Until these limitations are overcome, caution should be
used when interpreting whether NR3A-containing NMDARs are present or absent based on
the effects of pharmacological agonists/antagonists such as D-serine (Li and Han, 2006).
While NR3A shares more attributes with NR1 than with NR2 subunits, there are nonetheless
striking pharmacological differences between NR1 and NR3A subunits (Awobuluyi et al.,
2007; Nilsson et al., 2007a; Yao and Mayer, 2006). For example, NR1 binds the agonist ACPC
with higher affinity than ACBC, while the converse is true for NR3A (Yao and Mayer,
2006). Moreover, neither the partial agonist D-cycloserine nor the antagonist 7-
chlorokynurenic acid displace glycine binding to human NR3A expressed in HEK cells
(Nilsson et al., 2007a), in contrast to what is observed for the binding of glycine to NR1. The
differences between NR1 and NR3A subunits raise the exciting possibility that NR3A-specific
agonists or antagonists could be generated in the future to target diseases of NMDAR
dysfunction.
5.2 Antagonists
Very little is known about how NR3A-containing receptors can be pharmacologically blocked.
Studies to date have focused on the binding of NR1 antagonists to NR3A or have used
electrophysiological measures to determine how NR1/NR3A or NR1/NR2/NR3A heteromers
respond to typical NMDAR antagonists. When NR1/NR3A diheteromers are expressed in
heterologous systems, they exhibit little electrophysiological block by the classic NMDAR
antagonists APV, MK-801, or memantine (Chatterton et al., 2002). Triheteromeric receptors
containing NR1/NR2/NR3A are more difficult to isolate electrophysiologically because they
must be distinguished from either NR1/NR2 or NR1/NR3A receptors. However, this has been
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possible using single-channel recordings, which showed that the small conductance NR1/
NR2A/NR3A channel is blocked by D-APV (200 µM) (Sasaki et al., 2002). Interestingly, NR1/
NR2/NR3A triheteromeric receptors may also be blocked by antagonists targeting NR2
subunits, as receptors composed of NR1/NR2B/NR3A triheteromers and NR1/NR2B
diheteromers are similarly blocked by high concentrations of the NR2B-antagonist ifenprodil
(Smothers and Woodward, 2003). One might predict that, compared to NR1/NR2B
diheteromers, NR1/NR2B/NR3A triheteromers might be less sensitive to lower concentrations
of ifenprodil where NR2B-specificity is greater, as previous studies have shown that the
magnitude of ifenprodil block depends on the number of NR2B subunits contained within the
NMDAR complex (Hatton and Paoletti, 2005).
Studies of the ligand binding domain demonstrate that NR3A subunits interact with classical
NMDAR antagonists. Six of eight NR1 subunit antagonists exhibit more than a 100-fold larger
affinity for NR1 subunits compared to NR3A subunits (Yao and Mayer, 2006). For example,
kynurenic acid binds the NR1 ligand binding domain with high affinity (Kd= ~53 µM) but
only weakly binds the NR3A binding domain (Kd = ~15 mM) (Yao and Mayer, 2006). These
observations provide further evidence that NR1 and NR3A have distinct ligand binding
properties and increase the likelihood that specific agonists/antagonists could be designed to
target NR3A selectively. However, the extremely high affinity of NR3A for glycine indicates
that the design of competitive antagonists would require a particularly high affinity compound.
Thus, it might be more feasible to design non-competitive antagonists that act via allosteric
interactions with NR3A-containing NMDARs.
6. Intracellular binding partners
NMDAR-mediated effects can be initiated directly via ionic flow through the channel pore,
and can also be shaped by intracellular partners tethered to the NMDAR complex. To date,
few studies have examined interactions of NR3A with other proteins, but the existing reports
have identified possible associations between NR3A and protein phosphatases, cytoskeletal
proteins, and an adaptor protein implicated in receptor trafficking.
One specific C-terminal binding partner of NR3A is the catalytic subunit of protein phosphatase
2A (PP2A) (Chan and Sucher, 2001);(Ma and Sucher, 2004) (Figure 2). PP2A plays important
roles at postsynaptic sites, including dephosphorylating NR1 subunits on serine 897 (NR1-
S897). Dephosphorylation of NR1-S897 by PP2A attenuates NMDAR single-channel currents
and reduces permeability of the receptors to Ca2+. Importantly, activation of NMDARs causes
the physical uncoupling between NR3A and PP2A, decreasing PP2A activity at the synapse.
By influencing NR1 phosphorylation through its interaction with PP2A, NR3A may provide
a feedback mechanism to modulate NMDAR function based on the history of synaptic activity
(Chan and Sucher, 2001). Intriguingly, brains from schizophrenic patients have increased
dephosphorylation of NR1-S897 (Emamian et al., 2004) that might be related to overexpression
of NR3A (Ma and Sucher, 2004), providing a potential mechanism that could contribute to the
NMDAR hypofunction observed in schizophrenia.
In addition to modulating the activity of a phosphatase important to NMDARs, one intracellular
NR3A binding partner appears to be crucial for the removal of nascent NMDARs during
synapse maturation. NR3A binds PACSIN1/syndapin1, a neuron-specific intracellular adaptor
(Perez-Otano et al., 2006). PACSIN1 binds selectively to the C-terminus of NR3A (Figure 2)
through tertiary structure interactions with its NPF (Asn/Pro/Phe) motifs, recruiting a larger
complex with the endocytic proteins dynamin and clathrin and facilitating the rapid endocytosis
of NR3A-containing NMDARs. Disruption of this interaction results in the synaptic
accumulation of NR3A-containing NMDARs. The PACSIN1-mediated removal of NR3A-
containing NMDARs is activity-dependent, providing a mechanism for regulated receptor
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replacement that could drive the functional maturation of synaptic NMDARs during postnatal
development and the associated changes in the properties of synaptic plasticity.
Additional putative NR3A binding partners are beginning to be identified which could alter its
localization, trafficking, and signaling (Figure 2), but these interactions were only shown in
vitro and need to be extensively studied and verified. NR3A may interact with a cytoskeletal
protein (MAP1S/C19ORF5), a scaffolding protein (plectin), a cell cycle and apoptosis
regulatory protein (CARP-1), and a regulator of G-protein signaling (GPS2/AMF1) (Eriksson
et al., 2007a;Eriksson et al., 2007b). Confirmation of these associations would position NR3A
to play roles in intracellular processes such as trafficking and targeting of NR3A-containing
receptors (MAP1S and plectin), PKC activation (plectin), and suppression of the MAPK
pathway (GPS2/AMF1). Other NR3A binding partners will undoubtedly be identified, which
may link NR3A to more signaling pathways. Notably, there is a conspicuous absence of NR3A
interaction with the postsynaptic scaffolding protein PSD-95 (Eriksson et al., 2007a;Matsuda
et al., 2002), which may explain the labile synaptic expression of NR3A-containing NMDARs
(Perez-Otano et al., 2006). Alternatively, the clustering and stabilization of NR3A-containing
receptors near synaptic sites may rely on NR2 anchoring with other membrane-associated
guanylate kinase family scaffolding proteins, such as SAP102, which are present at high levels
in developing synapses (Perez-Otano et al., 2006;Sans et al., 2000;Wong et al., 2002).
7. Assembly, trafficking, and targeting of NR3-containing NMDARs
Developmental regulation of the membrane expression of different NMDAR subtypes shapes
synaptic and behavioral plasticity (Isaac et al., 1995; Liao et al., 1995; Philpot et al., 2001;
Quinlan et al., 1999; Roberts et al., 2009; Rumpel et al., 1998; Sawtell et al., 2003; Tang et
al., 1999; Wu et al., 1996). NMDARs can rapidly translocate in and out of synaptic regions
by lateral diffusion in the plane of the membrane and by endo/exocytic trafficking. It is
increasingly recognized that regulation of trafficking contributes to the synapse-specific and
activity-dependent control of NMDAR expression at individual synapses, by favoring local
receptor removal, insertion, or exchange (Lavezzari et al., 2004; Montgomery et al., 2005;
Scott et al., 2004; Washbourne et al., 2004).
Although peak expression of rodent NR3A occurs in the second postnatal week, its expression
levels and association with NR1 subunits may nonetheless be fairly limited compared to that
of NR2 subunits. Immunoprecipitation experiments found that, despite the majority of NR3A
associating with the obligatory NR1 subunit, NR3A subunits are likely to contribute only a
small fraction of the total receptor complex composition (Al-Hallaq et al., 2002). Specifically
at age P10, approximately 80% of NR3A subunits are associated with NR1, but less than 10%
of NR1, NR2A, and NR2B are bound to NR3A, and this association decreases further over
development. Strikingly, NR3A genetic deletion studies demonstrate that even a low NR3A
abundance is sufficient to have profound consequences on synapse formation and NMDAR-
mediated transmission during early postnatal development (Das et al., 1998; Perez-Otano et
al., 2001; Roberts et al., 2009; Sasaki et al., 2002; Tong et al., 2008).
Protein degradation, fluorescence recovery after photobleaching, and fluorescence resonance
energy transfer experiments suggest a central role for NR1 in the folding and assembly of
NMDAR heteromers in the endoplasmic reticulum (ER) (Atlason et al., 2007; Schuler et al.,
2008). Homomeric NR3 complexes fail to exit the ER, presumably because the C-terminus of
NR3A/NR3B carries a putative ER retention signal (RXR) (Figure 2). For forward secretory
trafficking and functional insertion into the plasma membrane to occur, the RXR motif is likely
masked by heteromeric assembly with NR1 subunits (Matsuda et al., 2003; Perez-Otano et
al., 2001; Schuler et al., 2008; Scott et al., 2001; Standley et al., 2000). However, NR3 subunits
may be rapidly degraded, even in the presence of NR1, resulting in inefficient assembly
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mechanisms or extremely rapid turnover of NR3A-containing NMDARs lacking NR2 subunits
(Atlason et al., 2007).
Once at the plasma membrane surface, the abundance and synaptic targeting of NR3A-
containing NMDARs appears to be highly regulated by synaptic activation of NMDARs. In
experiments using cultured hippocampal neurons transfected with GFP-tagged NR3A, intrinsic
neuronal activity induces the movement of NR3A-containing NMDARs from membrane and
synaptic locations to intracellular compartments (Perez-Otano et al., 2006).
Endocytic removal of NR3A can be facilitated by bath application of NMDA and prevented
by disruption of synaptic activity (TTX) or antagonism of NMDARs with APV. Furthermore,
removal relies upon a selective interaction with PACSIN1/syndapin1, a specialized accessory
protein involved in clathrin-mediated endocytosis and enriched at synapses (discussed in more
detail in Section 6). The synaptic expression of PACSIN1 is developmentally regulated and
exhibits a reciprocal expression pattern to that of NR3A (Perez-Otano et al., 2006), supporting
a role for PACSIN1 in the developmental downregulation of NR3A subunits.
Another regulator of NR3A synaptic targeting is the protein phosphatase PP2A, which binds
NR3A directly and influences the dephosphorylation state of NR1 subunits (Chan and Sucher,
2001; Ma and Sucher, 2004). PACSIN1 and PP2A binding domains on the C-terminus of
NR3A overlap (Figure 2), making it unlikely that these proteins would bind concurrently
(Chan and Sucher, 2001; Perez-Otano et al., 2006). Interestingly, NMDAR activation disrupts
the PP2A-NR3A protein interaction, and may unmask binding sites for PACSIN1, enabling
NR3A endocytosis.
Finally, PDZ-domain binding motifs, which provide areas of attachment for prototypical PSD
proteins and support the postsynaptic anchoring of other NMDAR subunits, are absent in the
C-termini of NR3A and NR3B (Eriksson et al., 2007a; Matsuda et al., 2002). Perhaps as a
consequence, these subunits are more loosely attached to the PSD than NR2 subunits (Perez-
Otano et al., 2006; Roberts et al., 2009). Despite this emerging set of data, and in contrast to
the large literature on NR2 subunits, little is yet known about how and where NR3 proteins
traffic.
8. Influence of NR3A subunits in the developing brain
NR3A is expressed in the right place at the right time to regulate spine and synapse
development. It is unclear, however, if the influence of NR3A is to serve as a ‘synaptic brake’
to limit synapse/spine formation or if it serves as a ‘synaptic marker’ to promote the elimination
of spines. These two hypotheses are not mutually exclusive and NR3A may influence both
processes.
8.1 Synaptic brake hypothesis
NR3A-containing receptors may act collectively as a synaptic brake. One possibility is that at
early stages, when their expression is highest, they limit synapse formation by raising the
threshold required for synaptic activity to induce synaptic maturation. Later in development,
activity-dependent removal of NR3A by PACSIN1/syndapin1 would relieve this brake and
allow the replacement of immature synaptic NMDARs by mature subtypes that are more stably
anchored to PSDs. Synapse maturation would then proceed with the recruitment of other
synaptic scaffolds and signaling complexes, and ensuing changes in spine morphology.
Synaptic plasticity mechanisms, such as LTP (long-term potentiation) and LTD (long-term
depression), influence the formation and stabilization of synapses and spines (Yuste and
Bonhoeffer, 2001) and are critically dependent upon Ca2+ entry via NMDARs (Lisman,
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1989). The dominant-negative effect of NR3A on current and Ca2+ flux has recently been
shown to limit synaptic plasticity (Roberts et al., 2009), providing a mechanism for NR3A
control of spine and synapse density. It will be interesting to determine whether NR3A
knockout mice display changes in synaptic plasticity that are causally related to the changes
in spine formation, or vice versa.
While Das and coworkers (1998) reported increased spine density and enlarged spines in the
cortex of P19 NR3A knockout mice, Tong et al. (2008) did not observe a related increase in
the frequency or amplitude of AMPAR mEPSC in the same brain region in P10-P13 mice.
However, the NMDAR/AMPAR ratio was enhanced, reflecting an increase in the NMDAR
component. This sequence of events makes it tempting to speculate that larger NMDAR
currents early in development favor enhanced LTP and subsequent increases in spine density/
size in NR3A-deficient mice. If true, the early developmental presence of NR3A may serve as
a synaptic brake to prevent the premature strengthening of synapses, and thus ensure a well-
coordinated strengthening and stabilization of only appropriate synapses in response to
experience. Early release of this brake in NR3A-null mutants would lead to enhanced spine
formation and maturation of inappropriate synapses.
8.2 Synaptic elimination hypothesis
Another hypothesis consistent with the phenotype of NR3A-null mice is that NR3A serves as
a tag to label weak synapses for elimination. In this scenario, coordinated or strong synaptic
activity could drive NR3A out of the synapse, possibly via activity- and NMDAR-dependent
synaptic removal of NR3A. Synapses with weak or uncoordinated activity would retain NR3A
and, hence, be targeted for elimination. NR3A may also facilitate the elimination of immature
synapses by recruiting the machinery necessary to exclude NMDARs from synapses, one of
the steps thought to underlie synapse elimination and spine loss, via its interaction with
PACSIN1/syndapin1 (Perez-Otano et al., 2006).
Another possible link between NR3A and spine elimination was suggested by the discovery
of a family of proteins termed “takusans” that are upregulated in NR3A-null mice and appear
to influence the formation of dendritic spines (Tu et al., 2007). Overexpression of takusans
enhances spine density, AMPAR expression, and PSD-95 clustering. Considering that the
expression of takusans is reciprocally regulated in development when compared to NR3A
subunits, NR3A may foster spine elimination by limiting the synaptic expression of takusan
proteins. No direct interaction between these proteins has been observed, and future studies
will be needed to investigate any causal relationship between NR3A and takusan expression.
9. NR3A in disease
9.1 Schizophrenia
A prominent theory is that impaired glutamatergic transmission contributes to the
pathophysiology of schizophrenia (Olney and Farber, 1995), and several lines of evidence
invoke an important role of NMDAR hypofunction (Coyle et al., 2003; Olney et al., 1999;
Tamminga, 1998; Tsai et al., 1998): (1) NMDAR antagonists, such as PCP, exacerbate
symptoms in patients with schizophrenia and produce symptoms nearly indistinguishable from
schizophrenia in normal individuals (Javitt and Zukin, 1991). Genetic or pharmacological
downregulation of NMDAR function in rodents also triggers schizophrenic-related behaviors
(Moghaddam and Jackson, 2003; Mohn et al., 1999). (2) NMDAR co-agonists, such as glycine
and D-serine, can improve cognitive functioning and alleviate negative symptoms associated
with schizophrenia (Goff et al., 1999; Goff et al., 1995; Heresco-Levy et al., 1996; Heresco-
Levy et al., 1998; Javitt, 2002; Javitt et al., 1994; Millan, 2005; Tsai et al., 1998). (3) Many
candidate schizophrenia genes influence NMDAR signaling and expression (Chowdari et al.,
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2002; Harrison and Weinberger, 2005; Martucci et al., 2003; Moghaddam, 2003; Straub et
al., 2002). For example, neuregulin, the protein product of a major schizophrenia susceptibility
gene, alters the surface expression of synaptic NMDARs (Gu et al., 2005; Ozaki et al., 1997;
Stefansson et al., 2004). (4) More recently, imaging studies have provided the first in vivo
evidence for reduced NMDAR binding in medication-free schizophrenic patients (Pilowsky
et al., 2006).
Although the mechanistic basis for NMDAR hypofunction in schizophrenia remains unknown,
it could be caused by a change in NMDAR subunit composition. To date there is little consensus
on alterations in NMDAR subunits that might contribute to the NMDAR hypofunction
observed in schizophrenia (Akbarian et al., 1996; Meador-Woodruff and Healy, 2000;
Moghaddam, 2003). However, a recent study demonstrated that NR3A mRNA levels are
increased within layer 5 in subregions of the dorsolateral prefrontal cortex in schizophrenics
(Mueller and Meador-Woodruff, 2004). This finding raises the possibility that inappropriate
expression of NR3A could exacerbate this subunit’s unique ability to suppress receptor activity,
and underlie NMDAR hypofunction. Consequences of aberrant expression would be predicted
to have a larger impact in the mature brain, where NR3A is remarkably downregulated in most
brain regions. Four further observations support a role for elevated NR3A in schizophrenia:
(1) Schizophrenic brains exhibit decreased phosphorylation of NR1 at serine 897, which can
be reversed by antipsychotics (Emamian et al., 2004). Because NR3A subunits form a signaling
complex with PP2A, which can dephosphorylate serine 897, overexpression of NR3A could
contribute to the reductions in NR1 phosphorylation in schizophrenia (Chan and Sucher,
2001). (2) Alterations in NR3A levels impair prepulse inhibition (Brody et al., 2005), a measure
of sensorimotor gating that is also impaired in many schizophrenia patients (Braff et al.,
2001). (3) Spine density is decreased in the DLPFC of schizophrenia patients (Glantz and
Lewis, 2000, 2001), a region where NR3A levels are elevated (Mueller and Meador-Woodruff,
2004), and elevated NR3A levels have been shown to decrease spine formation (Roberts et
al., 2009). (4) Impaired working memory in schizophrenia could be explained by deficits in
NMDAR function, potentially resulting from NR3A overexpression, in layer 5 pyramidal
neurons in the DLPFC (Fellous and Sejnowski, 2003; Sanchez-Vives and McCormick, 2000;
Sucher et al., 1995; Wong et al., 2002). Although it is now clear that NR3A levels are not
changed in a wholesale manner in the schizophrenic DLPFC (Henson et al., 2008), the above
data underscore a need to further examine regional changes in NR3A expression, protein
interactions, and signaling in schizophrenics and to evaluate if/how they contribute to the
pathophysiology of schizophrenia.
9.2 White matter injury
The dogma that NMDARs are expressed only in neurons within the CNS has been overturned,
and increasing evidence indicates not only that NMDARs are expressed in glia, but also that
glial NMDARs contain the NR3A subunit (Paoletti and Neyton, 2007). Three recent studies
highlighted the role of NMDARs in oligodendrocyte damage (Karadottir et al., 2005; Micu et
al., 2006; Salter and Fern, 2005), reporting that oligodendrocytes and the myelin sheaths they
form are damaged by excitotoxicity in a number of acute and chronic disorders, including
ischemic stroke, cerebral palsy, traumatic neural injury, and multiple sclerosis (Matute,
2006; Matute et al., 2007) (Figure 5). Both Ca2+ entry and subsequent oligodendrocyte damage
could be attenuated by NMDAR antagonists, indicating that white matter damage was caused
at least in part by NMDAR activation (Karadottir et al., 2005; Micu et al., 2006; Salter and
Fern, 2005). These studies demonstrated that NMDAR currents in oligodendrocytes failed to
show rectification at hyperpolarized potentials due to Mg2+ block, mimicking the behavior of
NR3A- or NR2C-containing NMDARs. This suggests that these NMDARs are positioned to
respond to glutamate activation, even in the absence of strong depolarization. Further, all three
studies showed that NR3A levels are high in myelin. Despite the low Ca2+ permeability of
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NR3A-containing NMDARs, high levels of NR3A-containing NMDARs and/or insufficient
Ca2+ buffering might predispose oligodendrocytes to cell death mediated by elevations of
glutamate associated with ischemic stroke or other excitotoxic events. If so, the development
of NR3A-selective antagonists could be of therapeutic benefit for preventing white matter
excitotoxic damage, with less severe adverse side effects than broad spectrum NMDAR
antagonists.
9.3 Diseases of neuronal excitotoxicity
A large number of neurological disorders are associated with increased excitotoxicity,
including Huntington’s disease (Fan and Raymond, 2007), Parkinson’s disease (Bonuccelli
and Del Dotto, 2006), Alzheimer’s disease (Wenk, 2006), chronic alcohol exposure (Crews et
al., 1998; Lovinger, 1993), and neuropathic pain (Dubner and Ruda, 1992). Other disorders
associated with excitotoxicity include acute brain injuries such as stroke (Martin et al., 1998),
epilepsy (Fujikawa, 2005; Meldrum, 1993), and traumatic injury (Arundine and Tymianski,
2004). Excessive activation of NMDARs is thought to contribute to excitotoxicity because the
depolarization-dependent activation of Ca2+ entry mediated by NMDARs can more readily
induce cell death compared to other forms of glutamatergic activation (Abdrachmanova et
al., 2002; Choi, 1992; Rothman and Olney, 1995). While excessive glutamate activity triggers
NMDAR-mediated cell death in most of these acute and chronic disorders, disruption of
cellular metabolic processes can also cause depolarization-induced activation of NMDARs by
shifting ionic balances (Zeevalk and Nicklas, 1992).
The proposed role of NMDAR-mediated excitotoxicity in neuronal disorders has fostered
intense research into the therapeutic benefits of NMDAR antagonists, but most efforts have
yielded disappointing results due to harmful side effects of the antagonists (Hoyte et al.,
2004; Lipton, 2006). Because NMDARs are crucial for so many neuronal functions, including
learning and memory (Bear, 1996), and because too little NMDAR activation can also lead to
apoptotic cell death (Ikonomidou et al., 1999), successful blockade of NMDAR-mediated
excitotoxicity must carefully attenuate NMDAR functions without eliminating them (Lipton,
2006). NR3A provides an attractive target for accomplishing this subtle manipulation of
NMDAR functions. One intriguing idea is that overexpression of NR3A might attenuate
NMDAR-mediated cell death by reducing Ca2+ permeability of existing NMDARs. However,
such an approach would have to carefully titrate the degree of NR3A overexpression, as
apoptosis can also be triggered by a dramatic decrease in NMDAR currents (Lipton and
Nakanishi, 1999).
A neuroprotective role for NR3A has recently been explored further by Nakanishi and
coworkers (2009), who used in vivo models of hypoxic-ischemic insults as well as retinal
cultures to examine the effects of NR3A on cell death. Using NR3A knockout and transgenic
overexpressing mice, these authors have provided convincing evidence that ischemic-induced
neuronal damage is extensive in the absence of NR3A, while the presence of NR3A reduces
cell loss (Table 2). Other recent observations support their findings, namely that retinal
ganglion cells are relatively invulnerable to NMDAR-mediated excitotoxicity in contrast to
many other neuronal classes (Ullian et al., 2004), and only the retinal cell types with high
NR3A content exhibit attenuated calcium responses to NMDA (Nakanishi et al., 2009; Sucher
et al., 2003). Consistent with the idea that NR3A might offer neuroprotective benefits, high
levels of NR3A expression during early brain development might explain why excitotoxicity
is not more prevalent at ages before the maturation of inhibitory circuitry. Perhaps it is not a
coincidence that NR3A levels diminish during development (Wong et al., 2002) as inhibition
increases (Coyle and Yamamura, 1976). These tantalizing correlations raise the possibility that
exogenous introduction of NR3A might be useful to treat a variety of neurological disorders
by preventing inappropriate cell death without producing deleterious side effects.
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9.4 Mental retardations associated with improper dendritic spine development
Dendritic spines are the major site for excitatory synaptic connections on neurons. Changes in
their number, density, and/or shape have been implicated in a number of mental retardations
including Fragile X, Rett, and Down syndromes (Carlisle and Kennedy, 2005; Chechlacz and
Gleeson, 2003; Fiala et al., 2002; Irwin et al., 2000; Kaufmann and Moser, 2000; Newey et
al., 2005), but the molecular basis for these spine abnormalities remains unknown. Activation
of NMDARs is required both for the bidirectional changes in synaptic strength thought to
underlie learning and memory (Malenka and Bear, 2004) and for the activity-dependent growth
or retraction of spines which may help encode enduring changes in synapses (Engert and
Bonhoeffer, 1999; Maletic-Savatic et al., 1999; Nagerl et al., 2004). Therefore, dysregulation
of NMDARs might contribute to abnormalities in spine number or shape that could be
prevented (or reverted) by normalizing NMDAR activity. Even if NMDAR dysfunction did
not play a causal role, modifying NMDAR function could potentially ameliorate conditions
arising from abnormal spine development. Indeed, one of the most striking phenotypes of mice
lacking NR3A is an approximate three to five-fold increase in spine density (Das et al.,
1998). Studies in mice that lack or overexpress NR3A should help elucidate links between
spine abnormalities and deficits in synaptic plasticity and learning, and hence evaluate if
targeted and carefully titrated exogenous modulation of NR3A could be of therapeutic value
in certain forms of mental retardation.
9.5 Other links of NR3A to clinical issues
NR3A is likely involved in other neurological conditions, yet possible roles for NR3A may
have gone unrecognized. NR3A was identified relatively recently, and, because of this, it was
not incorporated into many tests, such as gene array analyses, that could have detected its
involvement in disease. In addition to the direct and indirect suggestions of NR3A involvement
in neurological disorders mentioned above, we list here other possible links of NR3A to disease.
(1) Decreased NR3A mRNA and protein levels have been reported in patients with bipolar
disorder (Mueller and Meador-Woodruff, 2004). (2) Chronic low-level lead exposure during
development is associated with cognitive impairments in young children (Bellinger et al.,
1991), and decreased levels of NR3A mRNA are reported in rodent hippocampus after lead
exposure (Zhang et al., 2002). (3) Genetic analyses of NR3A in humans have identified a
common missense variation (Val362Met) that is associated with a strikingly different
prefrontal cortex activation during auditory target processing (Gallinat et al., 2007).
While these are just a few additional examples of how NR3A might be involved in neurological
disorders, the recognized involvement of NR3A is likely to increase as disease-related changes
in NR3A expression levels, polymorphisms, or function are evaluated. The above studies also
provide direct evidence for a functional role for NR3A in the adult human brain, and further
support the idea that modulation of NR3A in humans might alter neurological functions.
Development of specific agonists and antagonists of NR3A may thus be of therapeutic value
for a variety of neurological disorders. Intriguingly, exposure of rodents to weak magnetic
fields alters NR3A mRNA levels, raising the possibility that there may even be non-invasive
and non-pharmacological means to modify NR3A levels in humans (Hirai and Yoneda,
2004).
10. Concluding remarks
The use of many NMDAR agonists and antagonists had been abandoned because of their
limited therapeutic value in neurological disorders, largely due to their severe side effects.
Interest has peaked again because of tentative success at developing a new generation of non-
competitive (Lipton, 2006) and subunit-selective (Paoletti and Neyton, 2007) NMDAR
antagonists. The NR3A subunit represents a promising new therapeutic target, due to its unique
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dominant-negative suppression of NMDAR responses combined with its temporal and regional
distribution. However, before targeting of NR3A begins to hold any true therapeutic potential,
more research is needed. First, thorough studies of the temporal and regional specificity of
NR3A in humans need to be performed, as expression profiles of NR3A may differ dramatically
from rodents. Second, understanding how NR3A is trafficked to the plasma membrane,
especially to synaptic sites, needs to be refined before effects of modifying NR3A expression
levels or function can be predicted. Third, the role of NR3A at both extrasynaptic and synaptic
sites in mammalian cells needs to be rigorously examined, as most studies to date have used
heterologous expression systems. Fourth, parsing the reciprocal effects from gain-of-function
and loss-of-function analyses will clarify how NR3A affects cellular morphology, neuronal
circuit function, and cognition. Finally, specific agonists and antagonists of NR3A must be
generated, a prospect that appears feasible given the functional and pharmacological
differences between NR3A and other NMDAR subunits. The NR3A subunit has been receiving
exponentially increasing interest recently, and this continued trend is likely to drive the
identification of new NR3A functions and drug discovery.
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Schematic diagram of cDNA structures for human and rat NR3A. Both human and rat have
NR3A-1 isoforms, also known as NR3A-short (or -s). Rats also have an NR3A-2 isoform, also
known as NR3A-long (or -l). Exons 1–9 appear in blue filled boxes (E1-E9). Predicted
transmembrane (TM) domains 1–4 are indicated, and region of highest homology is between
TM 1 & 4. Lowest homology is found in the C-terminus, which corresponds to the area
following TM4. Location of the alternative splice variant (20-amino acid insert) in rodents is
denoted in white with an asterisk (*). Percent identity in exon 9 is between NR3A-short
sequences, and does not include the 20-amino acid insert found in rat.
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Putative transmembrane topology of rat NR3A. Predicted sites are shown for signal peptide
(SP), glycosylation (glyc), phosphorylation (PKC, CaMKII, PTK), and protein binding
(indicated by dotted lines for PACSIN1/syndapin1, MAP1S, PP2A, plectin, CARP1, and
GPS2). Sequence motifs (-CC-, -G-, -YTANLAAV-, -RXR-), transmembrane regions (TM1-
TM4) and the extracellular ligand-binding domain/glycine binding pocket (S1-S2) are noted.
Predicated kinase phosphorylation sites are indicated by open circles (○). A polyproline motif
is indicated by a single black circle (●). CaMKII site predicted for human but not rat is indicated
within a square symbol. MAP1 S and PP2A binding sites are overlapping and found just
intracellular to TM4. TM2 and TM3 segments are thought to form the channel pore. Alternative
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splicing in rodents but not humans produces a twenty amino acid insert (-
SRWRRWTCKTEGDSELSLFP-). This area contains potential phosphorylation sequences for
PKA, PKC, and CaMKII. Most sites have been proposed by sequence analysis and are not
verified. Amino acid numbers appear in orange. Figure based on sequence data from
(Andersson et al., 2001).
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(A) Schematic representation of NMDAR subunit expression in the developing rat brain. The
gray scale gradient shows the differences of each subunit relative to maximum, with the darkest
regions reflecting the strongest expression. NR3A appears to be expressed in similar temporal
fashion to NR2D, with subunits peaking between P7 and P14. This is contrasted with NR3B,
NR2A, and NR2C, which increase developmentally and peak in the third postnatal week.
Adapted with permission from (Lujan et al., 2005). (B) Schematic representation of NR3A
expression profile and potential roles in the developing human central nervous system. Several
key developmental processes in the brain characterize the early postnatal timeframe, when
NR3A is maximally expressed: axon and dendrite sprouting, synaptogenesis, myelination, cell
death, synapse maturation and elimination (de Graaf-Peters and Hadders-Algra, 2006). The
gray scale gradient illustrates the changes in NR3A expression levels, with the darkest regions
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(child/juvenile stages) reflecting the strongest expression, and low expression seen in the
lightest regions (fetal and adult life).
Henson et al. Page 29














The NR3 subfamily decreases NMDAR-mediated neurotransmission. (A) Model
demonstrating the influence of the NR3 subfamily on current flux through NMDARs.
NMDARs containing the glutamate-binding NR2 subunits (red) are highly permeable to
Ca2+ and dependent upon postsynaptic depolarization due to the Mg2+ block. Conversely,
NMDARs containing glycine-binding NR3 subunits (green) flux less current (“i”), are less
permeable to Ca2+, and are less sensitive to Mg2+ block. This is demonstrated in panels (B)
and (C) by single-channel recordings (used with permission from (Sasaki et al., 2002). These
recordings from outside-out patches are taken from oocytes expressing NR1/NR2A/NR3A
from injections of cRNA in a (B) 1:1:2 ratio or (C) 1:1:5 ratio and demonstrate the dominant-
Henson et al. Page 30













negative effects of the NR3 subunits on NMDAR-mediated neurotransmission. Dotted red line
in (B) indicates high conductance state of a putative NR1/NR2A-receptor, while dotted green
line in (C) indicates low conductance state of a putative NR1/NR2A/NR3A-receptor.
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NR3A-containing NMDARs may contribute to white matter damage with ischemia. High
concentrations of extracellular glutamate caused by reversal of glutamate transport during
ischemic conditions can make oligodendrocytes particularly vulnerable to injury. Unlike
traditional NMDARs, NR3A-containing receptors may be preferentially activated by
glutamate because they are found at high levels in oligodendrocytes and they are insensitive
to magnesium block. The resulting calcium influx through NR3A-NMDARs may be sufficient
to cause excitotoxic damage to oligodendrocyte processes, ultimately resulting in cell death
(indicated by brown color). Modified with permission from (Matute, 2006).
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Table 1
Developmental profile of NR3A expression patterns in rodent, monkey, and human brain. Consensus results of
mRNA and protein expression data are depicted as having high (dark), moderate (gray), weak (light gray), and
non-detectable (ND) levels of expression. Boxes with diagonal lines indicate no data available to date. Letters
within boxes denote references as matched below. Most studies have been conducted in rodents and reveal a
general pattern of low prenatal presence of NR3A that increases dramatically in the first two postnatal weeks,
and declines into adulthood. When both isoforms were reported, only data from expression of NR3A-short
sequences were considered. Note that this schematic is meant to present a general overview of NR3A expression,
but the schematic is unable to depict data reported from specific subregions/cell layers (for these details, see cited
manuscripts).
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Table 2
NR3A loss-of-function and gain-of-function studies demonstrate reciprocal effects in mutant mice.
Measurement NR3A-KO NR3A-OE References
Spine number and synapse size ↑ ↓ Das et al., 1998; Roberts et al., 2009
Magnitude of NMDAR-mediated currents ↑ ↓
Das et al., 1998; Perez-Otano et al., 2001;
Sasaki et al., 2002;
Tong et al., 2008; Roberts et al., 2009
NMDAR calcium permeability ↑ ↓ Perez-Otano et al., 2001; Sasaki et al., 2002;Sucher et al., 2003; Tong et al., 2008
Hyperpolarization-mediated block of NMDAR
currents by magnesium ↑ ↓ Sasaki et al., 2002; Tong et al., 2008; Roberts et al., 2009




↓ Roberts et al., 2009
- LTD (1 Hz; 15 min) No change No change
Cell death after ischemic-hypoxic insults ↑ ↓ Nakanishi et al., 2009
Spatial memory (Morris water maze) ND ↓ Roberts et al., 2009
Long-term memory (food preference and object
recognition)
ND ↓ Roberts et al., 2009




No change Brody et al., 2005
Abbreviations: NR3A-KO, NR3A knockout mouse; NR3A-OE, NR3A overexpressor mouse; LTP, long-term potentiation; LTD, long-term
depression; Hz, hertz; ND, no data.
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